inspection – Page 234

Process change implemented without QA approval during inspection preparation – regulatory impact assessment case study

Assessing the Regulatory Implications of Unapproved Process Changes During Inspection Preparation In a highly regulated industry like pharmaceuticals, deviations from established processes can lead to significant compliance issues, especially during…

Deviation recurrence across batches during tech transfer – root cause analysis failure explained

Analyzing Deviation Recurrence Across Batches During Technology Transfer: A Comprehensive Case Study In the robust environment of pharmaceutical manufacturing, maintaining compliance and ensuring product integrity is paramount. A notable challenge…

Critical IPC skipped during scale-up – FDA inspection observation breakdown

Investigation of Critical IPC Missing During Scale-Up and FDA Inspection Outcomes The successful scale-up of pharmaceutical products can be riddled with challenges, particularly in manufacturing controls where critical In-Process Controls…

Unapproved process parameter change during commercial campaign – CAPA ineffectiveness identified

Addressing Unapproved Process Parameter Changes During a Commercial Campaign In the realm of pharmaceutical manufacturing, adherence to established process parameters is paramount to ensure product quality and compliance with regulatory…

Process change implemented without QA approval during changeover – CAPA ineffectiveness identified

CAPA Ineffectiveness Revealed in Unauthorized Process Change During Changeover In the highly regulated pharmaceutical manufacturing industry, adherence to approved processes and quality systems is paramount. This case study explores a…

Unplanned hold time extension during tech transfer – root cause analysis failure explained

Analyzing Unplanned Hold Time Extensions During Tech Transfers: A Comprehensive Case Study Unplanned hold time extensions during technical transfers can pose significant risks to pharmaceutical manufacturing, raising concerns about product…

Unapproved process parameter change during scale-up – CAPA ineffectiveness identified

Examining Unapproved Process Parameter Changes During Scale-Up: A Case Study In pharmaceutical manufacturing, strict adherence to established process parameters is crucial to ensure product quality and compliance with regulatory standards.…

Deviation closed without effectiveness check during tech transfer – root cause analysis failure explained

Case Study: Addressing a Deviation Closed Without Effectiveness Check During Tech Transfer The pharmaceutical industry constantly grapples with the intricacies of manufacturing and quality assurance. One recurrent challenge emerges during…

Batch executed with expired SOP during inspection preparation – CAPA ineffectiveness identified

Addressing GMP Deviations: The Case of a Batch Executed with Expired SOP During Inspection Preparation In pharmaceutical manufacturing, maintaining compliance with Good Manufacturing Practices (GMP) is critical to ensuring product…

Unapproved process parameter change during commercial campaign – regulatory impact assessment case study

Case Study: Assessing the Impact of Unapproved Process Parameter Changes in a Commercial Environment In the highly regulated landscape of pharmaceutical manufacturing, adherence to established protocols is crucial for maintaining…

Critical IPC skipped during changeover – CAPA ineffectiveness identified

Investigation of a Critical IPC Omission During Changeover: A Case Study In the fast-paced environment of pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practices (GMP) is paramount. However, lapses can…

Critical IPC skipped during scale-up – regulatory impact assessment case study

Assessing the Regulatory Impact of Skipped Critical IPCs During Scale-Up In pharmaceutical manufacturing, ensuring the integrity of every process step is vital. A recent case study highlights a significant deviation…